Recognizing the importance of generating scientific evidence for traditional medicines, Dabur established the Dabur Research & Development Centre (DRDC) to undertake systematic research on the safety, pharmacological properties, mechanisms of action, and potential health benefits of its products, including Dabur Chyawanprash.
The scientific evaluation of DCP has progressively expanded from traditional knowledge and formulation-based rationale to investigations using modern pharmacological, toxicological, cellular, animal, mechanistic, and clinical approaches.
A component of this research programme has included preclinical investigations conducted in collaboration with Althea DRF Life Sciences, leveraging expertise in experimental pharmacology and biological evaluation. These collaborative studies have enabled the assessment of DCP using defined experimental models, measurable biological endpoints, and mechanistic investigations.
Preclinical investigations have included evaluation of the tolerability and safety of DCP in acute and repeated-dose studies. Additional experimental studies have investigated immune-related biological responses, including parameters associated with macrophage phagocytic activity, natural killer (NK) cell function, dendritic-cell maturation, and inflammatory mediators.
These investigations provide mechanistic evidence that can be considered alongside the traditional Ayurvedic concepts of Vyadhikshamatva, Ojas, and Rasayana, while recognizing that these traditional concepts do not have direct one-to-one equivalents in modern biomedical science.
Clinical Evaluation
The preclinical research programme has been complemented by clinical investigations evaluating Dabur Chyawanprash in different population groups and health contexts. Studies have included healthy individuals as well as populations investigated in relation to recurrent respiratory infections, allergic conditions, and seasonal health challenges.
The overall objective has been to build a structured evidence base for understanding the safety, biological activity, and potential mechanisms associated with a complex multi-ingredient Rasayana formulation.
Depending on the study design, clinical investigations have evaluated both clinical outcomes and objective biological parameters. These have included immunoglobulins such as IgE and IgG, complement components including C3 and C4, haematological parameters, respiratory measures, and health-related quality-of-life outcomes.
- IgE
- IgG
- C3
- C4
- Haematological parameters
- Respiratory measures
- Health-related quality of life
The integration of clinical outcomes with measurable biological biomarkers provides a more comprehensive approach to evaluating a complex polyherbal formulation and allows traditional indications to be examined using contemporary clinical research methodologies.